{"schema_version":"secwatch.filing_event.v1","accession":"0001387131-23-010995","form_type":"8-K","ticker":null,"cik":"0000887247","company_name":"DMK PHARMACEUTICALS Corp","filed_at":"2023-09-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.889857+00:00","generated_at":"2026-06-10T22:27:38.385197+00:00","sec_items":["5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Adamis Pharma changes name to DMK Pharmaceuticals, ticker to DMK, pivots to substance use disorders","bullets":["Adamis Pharmaceuticals renamed DMK Pharmaceuticals effective September 6, 2023; new Nasdaq ticker 'DMK' begins September 8, 2023.","Strategic focus shifts to small-molecule therapies for substance use disorders, including opioid overdose treatment ZIMHI® and clinical compound DPI-125.","DPI-125 targets opioid use disorder and moderate-to-severe pain; company expects milestones by end 2024 including transdermal delivery, safety study, and abuse liability study.","No stockholder vote required; CUSIP unchanged; no impact on existing shareholder rights."],"urls":{"canonical":"https://secwatch.observer/filing/0001387131-23-010995","json":"https://secwatch.observer/filing/0001387131-23-010995.json","markdown":"https://secwatch.observer/filing/0001387131-23-010995.md","text":"https://secwatch.observer/filing/0001387131-23-010995.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/887247/000138713123010995/0001387131-23-010995-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/887247/000138713123010995/dmk-8k_090623.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T22:27:38.385197+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a3b3d31b0ff3ad3de07d13274bd72d0258440444","claim":"DMK PHARMACEUTICALS Corp: Company changed its corporate name from Adamis Pharmaceuticals Corporation to DMK Pharmaceuticals Corporation via a certificate of amendment to the restated certificate of incorporation (effective 2023-09-06).","evidence_excerpt":"Effective September 6, 2023, Adamis Pharmaceuticals Corporation (the “Company”) changed its corporate name to DMK Pharmaceuticals Corporation (the “Name Change”) pursuant to a certificate of amendment to the Company’s restated certificate of incorporation (the “Charter Amendment”) filed with the Secretary of State of Delaware.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/887247/000138713123010995/0001387131-23-010995-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-09-06"}],"fact_type":"governance_change"},{"claim_id":"b199e02d78fa79c2d0a1c542bc3baf9acbcd1b31","claim":"DMK PHARMACEUTICALS Corp: Amended and restated its Amended and Restated Bylaws to reflect the name change to DMK Pharmaceuticals Corporation (effective 2023-09-06).","evidence_excerpt":"On the effective date of the Name Change the Company also amended and restated its Amended and Restated Bylaws (the “Amended and Restated Bylaws”), to reflect the Name Change.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/887247/000138713123010995/0001387131-23-010995-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2023-09-06"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}